Murilo Guedes1,2, Daniel G Muenz2, Jarcy Zee2, Brian Bieber2, Benedicte Stengel3, Ziad A Massy3,4, Nicolas Mansencal5, Michelle M Y Wong6, David M Charytan7, Helmut Reichel8, Sandra Waechter9, Ronald L Pisoni2, Bruce M Robinson2, Roberto Pecoits-Filho. 1. Pontificia Universidade Catolica do Parana, Curitiba, Brazil. 2. Arbor Research Collaborative for Health, Ann Arbor, Michigan. 3. Université Paris Saclay, Villejuif, France. 4. Service de Néphrologie et Dialyse, Assistance Publique Hôpitaux de Paris, Hôpital Universitaire Ambroise Paré, Boulogne Billancourt, France. 5. Service de Cardiologie Assistance Publique Hôpitaux de Paris, Hôpital Universitaire Ambroise Paré, Boulogne Billancourt, France. 6. Department of Medicine, University of British Columbia, Vancouver, Canada. 7. NYU Langone Health, New York, New York. 8. Nephrological Center, Villingen-Schwenningen, Germany. 9. Vifor Pharma Ltd., Glattbrugg, Zurich, Switzerland.
Abstract
BACKGROUND: Approximately 30%-45% of patients with nondialysis CKD have iron deficiency. Iron therapy in CKD has focused primarily on supporting erythropoiesis. In patients with or without anemia, there has not been a comprehensive approach to estimating the association between serum biomarkers of iron stores, and mortality and cardiovascular event risks. METHODS: The study included 5145 patients from Brazil, France, the United States, and Germany enrolled in the Chronic Kidney Disease Outcomes and Practice Patterns Study, with first available transferrin saturation (TSAT) and ferritin levels as exposure variables. We used Cox models to estimate hazard ratios (HRs) for all-cause mortality and major adverse cardiovascular events (MACE), with progressive adjustment for potentially confounding variables. We also used linear spline models to further evaluate functional forms of the exposure-outcome associations. RESULTS: Compared with patients with a TSAT of 26%-35%, those with a TSAT ≤15% had the highest adjusted risks for all-cause mortality and MACE. Spline analysis found the lowest risk at TSAT 40% for all-cause mortality and MACE. Risk of all-cause mortality, but not MACE, was also elevated at TSAT ≥46%. Effect estimates were similar after adjustment for hemoglobin. For ferritin, no directional associations were apparent, except for elevated all-cause mortality at ferritin ≥300 ng/ml. CONCLUSIONS: Iron deficiency, as captured by TSAT, is associated with higher risk of all-cause mortality and MACE in patients with nondialysis CKD, with or without anemia. Interventional studies evaluating the effect on clinical outcomes of iron supplementation and therapies for alternative targets are needed to better inform strategies for administering exogenous iron.
BACKGROUND: Approximately 30%-45% of patients with nondialysis CKD have iron deficiency. Iron therapy in CKD has focused primarily on supporting erythropoiesis. In patients with or without anemia, there has not been a comprehensive approach to estimating the association between serum biomarkers of iron stores, and mortality and cardiovascular event risks. METHODS: The study included 5145 patients from Brazil, France, the United States, and Germany enrolled in the Chronic Kidney Disease Outcomes and Practice Patterns Study, with first available transferrin saturation (TSAT) and ferritin levels as exposure variables. We used Cox models to estimate hazard ratios (HRs) for all-cause mortality and major adverse cardiovascular events (MACE), with progressive adjustment for potentially confounding variables. We also used linear spline models to further evaluate functional forms of the exposure-outcome associations. RESULTS: Compared with patients with a TSAT of 26%-35%, those with a TSAT ≤15% had the highest adjusted risks for all-cause mortality and MACE. Spline analysis found the lowest risk at TSAT 40% for all-cause mortality and MACE. Risk of all-cause mortality, but not MACE, was also elevated at TSAT ≥46%. Effect estimates were similar after adjustment for hemoglobin. For ferritin, no directional associations were apparent, except for elevated all-cause mortality at ferritin ≥300 ng/ml. CONCLUSIONS: Iron deficiency, as captured by TSAT, is associated with higher risk of all-cause mortality and MACE in patients with nondialysis CKD, with or without anemia. Interventional studies evaluating the effect on clinical outcomes of iron supplementation and therapies for alternative targets are needed to better inform strategies for administering exogenous iron.
Authors: Jay B Wish; George R Aronoff; Bruce R Bacon; Carlo Brugnara; Kai-Uwe Eckardt; Tomas Ganz; Iain C Macdougall; Julio Núñez; Adam J Perahia; John C Wood Journal: Am J Nephrol Date: 2018-02-13 Impact factor: 3.754
Authors: Monique E Cho; Jared L Hansen; Celena B Peters; Alfred K Cheung; Tom Greene; Brian C Sauer Journal: Kidney Int Date: 2019-05-15 Impact factor: 10.612
Authors: Stefan D Anker; Bridget-Anne Kirwan; Dirk J van Veldhuisen; Gerasimos Filippatos; Josep Comin-Colet; Frank Ruschitzka; Thomas F Lüscher; Gregory P Arutyunov; Michael Motro; Claudio Mori; Bernard Roubert; Stuart J Pocock; Piotr Ponikowski Journal: Eur J Heart Fail Date: 2017-04-24 Impact factor: 15.534
Authors: Piotr Ponikowski; Bridget-Anne Kirwan; Stefan D Anker; Theresa McDonagh; Maria Dorobantu; Jarosław Drozdz; Vincent Fabien; Gerasimos Filippatos; Udo Michael Göhring; Andre Keren; Irakli Khintibidze; Hans Kragten; Felipe A Martinez; Marco Metra; Davor Milicic; José C Nicolau; Marcus Ohlsson; Alexander Parkhomenko; Domingo A Pascual-Figal; Frank Ruschitzka; David Sim; Hadi Skouri; Peter van der Meer; Basil S Lewis; Josep Comin-Colet; Stephan von Haehling; Alain Cohen-Solal; Nicolas Danchin; Wolfram Doehner; Henry J Dargie; Michael Motro; Javed Butler; Tim Friede; Klaus H Jensen; Stuart Pocock; Ewa A Jankowska Journal: Lancet Date: 2020-11-13 Impact factor: 79.321
Authors: Stefan D Anker; Josep Comin Colet; Gerasimos Filippatos; Ronnie Willenheimer; Kenneth Dickstein; Helmut Drexler; Thomas F Lüscher; Boris Bart; Waldemar Banasiak; Joanna Niegowska; Bridget-Anne Kirwan; Claudio Mori; Barbara von Eisenhart Rothe; Stuart J Pocock; Philip A Poole-Wilson; Piotr Ponikowski Journal: N Engl J Med Date: 2009-11-17 Impact factor: 91.245
Authors: Marcelo Barreto Lopes; Charlotte Tu; Jarcy Zee; Murilo Guedes; Ronald L Pisoni; Bruce M Robinson; Bryce Foote; Katarina Hedman; Glen James; Antonio Alberto Lopes; Ziad Massy; Helmut Reichel; James Sloand; Sandra Waechter; Michelle M Y Wong; Roberto Pecoits-Filho Journal: Sci Rep Date: 2021-01-19 Impact factor: 4.379
Authors: Sunil Bhandari; Philip A Kalra; Mario Berkowitz; Diogo Belo; Lars L Thomsen; Myles Wolf Journal: Nephrol Dial Transplant Date: 2021-01-01 Impact factor: 5.992
Authors: Kristian Hveem; Cristen J Willer; Ben M Brumpton; Marta R Moksnes; Sarah E Graham; Kuan-Han Wu; Ailin Falkmo Hansen; Sarah A Gagliano Taliun; Wei Zhou; Ketil Thorstensen; Lars G Fritsche; Dipender Gill; Amy Mason; Francesco Cucca; David Schlessinger; Gonçalo R Abecasis; Stephen Burgess; Bjørn Olav Åsvold; Jonas B Nielsen Journal: Commun Biol Date: 2022-06-16
Authors: Ana Beatriz Lesqueves Barra; Ana Paula Roque-da-Silva; Maria Eugenia F Canziani; Jocemir R Lugon; Jorge Paulo Strogoff-de-Matos Journal: BMC Nephrol Date: 2022-02-23 Impact factor: 2.388